Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1989-1-26
|
pubmed:language |
bul
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0450-2167
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
30-2
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2462076-Aged,
pubmed-meshheading:2462076-Drug Evaluation,
pubmed-meshheading:2462076-Humans,
pubmed-meshheading:2462076-Male,
pubmed-meshheading:2462076-Middle Aged,
pubmed-meshheading:2462076-Phenoxybenzamine,
pubmed-meshheading:2462076-Prostatic Hyperplasia,
pubmed-meshheading:2462076-Urodynamics
|
pubmed:year |
1988
|
pubmed:articleTitle |
[Therapeutic potentials of the preparation dibenziran in patients with prostatic adenoma].
|
pubmed:publicationType |
Journal Article
|